Just three years into its inception, WindRose Health Investors’ Lykan Bioscience combined with GHO Capital’s RoslinCT to create what the co-CEOs believe is the largest transatlantic pure play cell therapy CDMO.
Why it matters: A red-hot area of investment, cell and gene therapy is also a fast-growing pocket of science poised to transform medicine. In tandem, demand is growing for infrastructure to make drug development faster and more efficient and cost effective.
/2022/08/15/1660577840257.gif?w=3840)
